Comparative Pharmacology
Head-to-head clinical analysis: DUAKLIR PRESSAIR versus DULERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUAKLIR PRESSAIR versus DULERA.
DUAKLIR PRESSAIR vs DULERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dual bronchodilator combining a long-acting muscarinic antagonist (aclidinium) and a long-acting beta2-agonist (formoterol). Aclidinium inhibits acetylcholine at M3 receptors, reducing bronchoconstriction; formoterol stimulates beta2-adrenergic receptors, relaxing airway smooth muscle.
DULERA is a combination of formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA), and mometasone furoate, a corticosteroid. Formoterol acts by relaxing bronchial smooth muscle via beta2-receptor activation. Mometasone furoate reduces inflammation in the lungs by inhibiting inflammatory mediators and suppressing immune responses.
1 inhalation (aclidinium 400 mcg / formoterol 12 mcg) twice daily.
Inhalation: 2 inhalations twice daily (morning and evening). Each inhalation delivers mometasone furoate 100/200 mcg and formoterol fumarate 5 mcg.
None Documented
None Documented
Terminal half-life 5.0–6.5 hours (aclidinium); steady-state reached within 2 days; no accumulation at therapeutic doses
Formoterol: terminal half-life 10-14 hours (supports twice-daily dosing); Mometasone: terminal half-life 13.8 hours (range 10-20 hours) after inhalation.
Renal (55% as unchanged aclidinium; 20% as metabolites); biliary/fecal (33% as metabolites and parent)
Formoterol: 10-15% renal as unchanged drug and metabolites, remainder hepatically cleared; Mometasone: >99% biliary/fecal as metabolites, <1% renal unchanged.
Category C
Category C
Anticholinergic/Beta2-Agonist Combination
Corticosteroid/Beta2-Agonist Combination